15 Jul 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250715103754/en/KalVista-Pharmaceuticals-Announces-UK-MHRA-Approval-of-EKTERLY-sebetralstat-First-and-Only-Oral-On-demand-Treatment-for-Hereditary-Angioedema
10 Jul 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250710831184/en/KalVista-Pharmaceuticals-Provides-Operational-Update-and-Fiscal-Year-2025-Financial-Results
07 Jul 2025
// PRESS RELEASE
https://ir.kalvista.com/news-releases/news-release-details/kalvista-pharmaceuticals-announces-fda-approval-ekterlyr
07 Jul 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/orsini-selected-as-specialty-pharmacy-partner-for-kalvistas-ekterly-sebetralstat-302498995.html
26 Jun 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250626645779/en/KalVista-Pharmaceuticals-Enters-into-Licensing-Agreement-with-Pendopharm-to-Commercialize-Sebetralstat-for-HAE-in-Canada
13 Jun 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250613608281/en/KalVista-Pharmaceuticals-Announces-FDA-Will-Not-Meet-PDUFA-Goal-Date-for-Sebetralstat-NDA-for-Hereditary-Angioedema-Due-to-FDA-Resource-Constraints